B-intervention	0	5	Brief
I-intervention	6	13	smoking
I-intervention	14	23	cessation
O	24	36	intervention
O	37	39	in
O	40	48	relation
O	49	51	to
O	52	58	breast
O	59	65	cancer
O	66	73	surgery
O	73	74	:
O	75	76	a
O	77	87	randomized
O	88	98	controlled
O	99	104	trial
O	104	105	.

O	106	113	Smokers
O	114	117	are
O	118	122	more
O	123	128	prone
O	129	131	to
O	132	139	develop
O	140	153	postoperative
O	154	167	complications
O	167	168	.

O	169	176	Smoking
O	177	186	cessation
O	187	199	intervention
O	200	209	beginning
O	210	211	4
O	211	212	-
O	212	213	8
O	214	219	weeks
O	220	225	prior
O	226	228	to
O	229	236	surgery
O	237	245	improves
O	246	249	the
O	250	263	postoperative
O	264	271	outcome
O	271	272	.

O	273	279	Cancer
O	280	288	patients
O	288	289	,
O	290	297	however
O	297	298	,
O	299	304	often
O	305	312	undergo
O	313	320	surgery
O	321	325	less
O	326	330	than
O	331	332	4
O	333	338	weeks
O	339	344	after
O	345	354	diagnosis
O	354	355	.

O	356	359	The
O	360	367	primary
O	368	377	objective
O	378	380	of
O	381	385	this
O	386	391	study
O	392	395	was
O	396	405	therefore
O	406	408	to
O	409	416	examine
O	417	419	if
O	420	421	a
O	422	427	brief
O	428	435	smoking
O	436	445	cessation
O	446	458	intervention
O	459	466	shortly
O	467	473	before
O	474	480	breast
O	481	487	cancer
O	488	495	surgery
O	496	501	would
O	502	511	influence
O	512	525	postoperative
O	526	539	complications
O	540	543	and
O	544	551	smoking
O	552	561	cessation
O	561	562	.

O	563	564	A
O	565	575	randomized
O	576	586	controlled
O	587	598	multicentre
O	599	604	trial
O	605	609	with
O	610	617	blinded
O	618	625	outcome
O	626	636	assessment
O	637	646	conducted
O	647	649	at
O	650	651	3
O	652	661	hospitals
O	662	664	in
B-location	665	672	Denmark
O	672	673	.

B-total-participants	674	677	One
I-total-participants	678	685	hundred
I-total-participants	686	689	and
I-total-participants	690	696	thirty
O	697	705	patients
O	706	710	were
O	711	719	randomly
O	720	728	assigned
O	729	731	to
O	732	737	brief
O	738	745	smoking
O	746	758	intervention
O	759	760	(
O	760	761	n
O	762	763	=
B-intervention-participants	764	766	65
O	766	767	)
O	768	770	or
B-control	771	779	standard
I-control	780	784	care
O	785	786	(
O	786	787	n
O	788	789	=
B-control-participants	790	792	65
O	792	793	)
O	793	794	.

O	795	798	The
O	799	811	intervention
O	812	820	followed
O	821	824	the
O	825	835	principles
O	836	838	of
O	839	851	motivational
O	852	864	interviewing
O	865	868	and
O	869	877	included
O	878	890	personalized
O	891	899	nicotine
O	900	911	replacement
O	912	919	therapy
O	920	925	aimed
O	926	928	at
O	929	939	supporting
O	940	947	smoking
O	948	957	cessation
O	958	962	from
O	963	964	2
O	965	969	days
O	970	976	before
O	977	979	to
O	980	982	10
O	983	987	days
O	988	993	after
O	994	1001	surgery
O	1001	1002	.

O	1003	1006	The
B-outcome	1007	1014	overall
I-outcome	1015	1028	postoperative
I-outcome	1029	1041	complication
I-outcome	1042	1046	rate
O	1047	1048	(
O	1048	1057	including
O	1058	1064	seroma
O	1065	1074	requiring
O	1075	1085	aspiration
O	1085	1086	)
O	1087	1090	was
B-iv-bin-percent	1091	1093	61
I-iv-bin-percent	1093	1094	%
O	1095	1097	in
O	1098	1102	both
O	1103	1109	groups
O	1110	1114	risk
O	1115	1120	ratio
O	1121	1122	(
O	1122	1124	RR
O	1124	1125	)
O	1126	1127	1
O	1127	1128	.
O	1128	1130	00
O	1131	1132	(
O	1132	1134	95
O	1134	1135	%
O	1136	1138	CI
O	1139	1140	0
O	1140	1141	.
O	1141	1143	75
O	1143	1144	-
O	1144	1145	1
O	1145	1146	.
O	1146	1148	33
O	1148	1149	)
O	1149	1150	.

O	1151	1154	The
B-outcome	1155	1160	wound
I-outcome	1161	1173	complication
I-outcome	1174	1178	rate
O	1179	1182	was
B-iv-bin-percent	1183	1185	44
I-iv-bin-percent	1185	1186	%
O	1187	1193	versus
B-cv-bin-percent	1194	1196	45
I-cv-bin-percent	1196	1197	%
O	1197	1198	.

O	1199	1202	The
B-outcome	1203	1209	effect
I-outcome	1210	1212	on
I-outcome	1213	1226	perioperative
I-outcome	1227	1234	smoking
I-outcome	1235	1244	cessation
O	1245	1248	was
O	1249	1255	modest
O	1255	1256	,
B-iv-bin-percent	1257	1259	28
I-iv-bin-percent	1259	1260	%
O	1261	1273	intervention
O	1274	1280	versus
B-cv-bin-percent	1281	1283	11
I-cv-bin-percent	1283	1284	%
O	1285	1292	control
O	1293	1298	group
O	1299	1307	patients
O	1307	1308	,
O	1309	1311	RR
O	1312	1313	2
O	1313	1314	.
O	1314	1316	49
O	1317	1318	(
O	1318	1320	95
O	1320	1321	%
O	1322	1324	CI
O	1325	1326	1
O	1326	1327	.
O	1327	1329	10
O	1329	1330	-
O	1330	1331	5
O	1331	1332	.
O	1332	1334	60
O	1334	1335	)
O	1335	1336	.

O	1337	1342	There
O	1343	1346	was
O	1347	1349	no
B-outcome	1350	1356	effect
I-outcome	1357	1359	on
I-outcome	1360	1367	smoking
I-outcome	1368	1377	cessation
O	1378	1380	at
O	1381	1383	12
O	1384	1390	months
O	1390	1391	,
B-iv-bin-percent	1392	1394	13
I-iv-bin-percent	1394	1395	%
O	1396	1402	versus
B-cv-bin-percent	1403	1404	9
I-cv-bin-percent	1404	1405	%
O	1405	1406	.

O	1407	1412	Brief
O	1413	1420	smoking
O	1421	1433	intervention
O	1434	1446	administered
O	1447	1454	shortly
O	1455	1461	before
O	1462	1468	breast
O	1469	1475	cancer
O	1476	1483	surgery
O	1484	1492	modestly
O	1493	1502	increased
O	1503	1507	self
O	1507	1508	-
O	1508	1516	reported
O	1517	1530	perioperative
O	1531	1538	smoking
O	1539	1548	cessation
O	1549	1556	without
O	1557	1563	having
O	1564	1567	any
O	1568	1576	clinical
O	1577	1583	impact
O	1584	1586	on
O	1587	1600	postoperative
O	1601	1614	complications
O	1614	1615	.

O	1616	1619	The
O	1620	1625	study
O	1626	1630	adds
O	1631	1633	to
O	1634	1637	the
O	1638	1642	body
O	1643	1645	of
O	1646	1654	evidence
O	1655	1665	indicating
O	1666	1670	that
O	1671	1676	brief
O	1677	1689	intervention
O	1690	1693	has
O	1694	1696	no
O	1697	1705	clinical
O	1706	1716	importance
O	1717	1720	for
O	1721	1729	surgical
O	1730	1738	patients
O	1739	1741	in
O	1742	1748	regard
O	1749	1751	to
O	1752	1765	postoperative
O	1766	1775	morbidity
O	1775	1776	.

O	1777	1783	Future
O	1784	1791	studies
O	1792	1798	should
O	1799	1801	be
O	1802	1810	designed
O	1811	1813	to
O	1814	1823	determine
O	1824	1827	the
O	1828	1835	optimal
O	1836	1840	time
O	1841	1843	of
O	1844	1851	smoking
O	1852	1861	cessation
O	1862	1868	before
O	1869	1876	surgery
O	1876	1877	.
